JP2005530732A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530732A5 JP2005530732A5 JP2003584094A JP2003584094A JP2005530732A5 JP 2005530732 A5 JP2005530732 A5 JP 2005530732A5 JP 2003584094 A JP2003584094 A JP 2003584094A JP 2003584094 A JP2003584094 A JP 2003584094A JP 2005530732 A5 JP2005530732 A5 JP 2005530732A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- pharmaceutical composition
- composition according
- compound
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100003818 GCG Human genes 0.000 claims description 13
- 101710042131 GCG Proteins 0.000 claims description 12
- 101700071595 GRZ1 Proteins 0.000 claims description 12
- 101700078733 ZGLP1 Proteins 0.000 claims description 12
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 9
- 108010090776 Glucagon-like peptide 1(7-37) Proteins 0.000 claims description 3
- MDXYQVPFSHFPHS-CVYXXLPWSA-N IRP peptide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C(C)C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)OC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCCCN)C1=CC=CC=C1 MDXYQVPFSHFPHS-CVYXXLPWSA-N 0.000 claims description 2
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- -1 GLP-1 compound Chemical class 0.000 claims 11
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 3
- 101700062901 DPP Proteins 0.000 claims 1
- 102100012353 DPP4 Human genes 0.000 claims 1
- 101700039720 DPP4 Proteins 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 101700024131 EXE4 Proteins 0.000 claims 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 1
- 229960002989 Glutamic Acid Drugs 0.000 claims 1
- 239000004471 Glycine Chemical group 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 208000007542 Paresis Diseases 0.000 claims 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 230000002496 gastric Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
Description
生物学的に活性な形態のネイティブなGLP-1は、GLP-1(7-37)OHおよびGLP-1(7-36)アミドとして公知の２種の短縮型ペプチドである。これら２つの天然に存在する短縮型GLP-1ペプチドは式Ｉ配列番号１に表されている。
（配列中、37位のXaaはGlyまたは-NH2である。）
Claims (15)
- GLP-1化合物を有効量で含有する、胃不全麻痺に罹患した患者を治療するための医薬組成物。
- 該患者が糖尿病にも罹患している請求項１に記載の医薬組成物。
- 該患者が２型糖尿病に罹患している、請求項２に記載の医薬組成物。
- GLP-1化合物がGLP-1(7-36)アミド、GLP-1(7-37)、GLP-1アナログおよびGLP-1誘導体からなる群から選択される、請求項１〜３のいずれか１項に記載の医薬組成物。
- GLP-1化合物がExendin-4、Exendin-4アナログおよびExendin-4誘導体からなる群から選択される、請求項１〜３のいずれか１項に記載の医薬組成物。
- GLP-1化合物がGLP-1レセプターのアゴニストである、請求項１〜３のいずれか１項に記載の医薬組成物。
- GLP-1化合物がDPP-IV耐性アナログである、請求項１〜３のいずれか１項に記載の医薬組成物。
- GLP-1化合物が22位にグルタミン酸を有するGLP-1アナログまたは誘導体である、請求項７に記載の医薬組成物。
- GLP-1化合物が８位にバリンまたはグリシンを有するGLP-1アナログである、請求項７に記載の医薬組成物。
- GLP-1化合物がGLP-1誘導体である、請求項１〜３のいずれか１項に記載の医薬組成物。
- GLP-1誘導体がアシル化GLP-1アナログである、請求項１０に記載の医薬組成物。
- GLP-1誘導体がArg34Lys26-(N-ε-(γ-Glu(N-α-ヘキサデカノイル)))-GLP-1(7-37)である、請求項１１に記載の医薬組成物。
- GLP-1化合物の皮下注射投与に用いるための、請求項１〜１２のいずれか１項に記載の医薬組成物。
- GLP-1化合物の経口投与に用いるための、請求項１〜１２のいずれか１項に記載の医薬組成物。
- GLP-1化合物の口腔内投与に用いるための、請求項１〜１２のいずれか１項に記載の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37165002P | 2002-04-10 | 2002-04-10 | |
| PCT/US2003/008457 WO2003087139A2 (en) | 2002-04-10 | 2003-03-27 | Treatment of gastroparesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530732A JP2005530732A (ja) | 2005-10-13 |
| JP2005530732A5 true JP2005530732A5 (ja) | 2006-05-18 |
Family
ID=29250714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003584094A Pending JP2005530732A (ja) | 2002-04-10 | 2003-03-27 | 胃不全麻痺の治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050164925A1 (ja) |
| EP (1) | EP1496924A4 (ja) |
| JP (1) | JP2005530732A (ja) |
| KR (1) | KR20040098063A (ja) |
| CN (1) | CN1735423A (ja) |
| AU (1) | AU2003220403A1 (ja) |
| BR (1) | BR0308904A (ja) |
| CA (1) | CA2480858A1 (ja) |
| EA (1) | EA200401345A1 (ja) |
| EC (1) | ECSP045345A (ja) |
| HR (1) | HRP20040939A2 (ja) |
| IL (1) | IL164266A0 (ja) |
| MX (1) | MXPA04009929A (ja) |
| NO (1) | NO20044815L (ja) |
| NZ (1) | NZ535684A (ja) |
| PL (1) | PL373658A1 (ja) |
| WO (1) | WO2003087139A2 (ja) |
| ZA (1) | ZA200408111B (ja) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
| US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
| TW200522976A (en) * | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
| EP1670515A2 (en) * | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| EP1793891B1 (en) | 2004-08-18 | 2011-11-09 | Metacure Limited | Monitoring, analysis, and regulation of eating habits |
| US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
| US9339190B2 (en) | 2005-02-17 | 2016-05-17 | Metacure Limited | Charger with data transfer capabilities |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| KR20070120112A (ko) | 2005-03-18 | 2007-12-21 | 노보 노르디스크 에이/에스 | 연장형 ｇｌｐ-1 화합물 |
| WO2006129321A2 (en) | 2005-06-02 | 2006-12-07 | Metacure N.V. | Gi lead implantation |
| US8463404B2 (en) | 2005-03-24 | 2013-06-11 | Metacure Limited | Electrode assemblies, tools, and methods for gastric wall implantation |
| WO2006102626A2 (en) * | 2005-03-24 | 2006-09-28 | Metacure Nv | Wireless leads for gastrointestinal tract applications |
| US8442841B2 (en) * | 2005-10-20 | 2013-05-14 | Matacure N.V. | Patient selection method for assisting weight loss |
| US8295932B2 (en) | 2005-12-05 | 2012-10-23 | Metacure Limited | Ingestible capsule for appetite regulation |
| AU2012203915B9 (en) * | 2006-04-20 | 2014-10-09 | Amgen Inc. | GLP-1 compounds |
| EP2574624A1 (en) * | 2006-04-20 | 2013-04-03 | Amgen Inc. | GLP-1 compounds |
| WO2008139463A2 (en) * | 2007-05-09 | 2008-11-20 | Metacure Ltd. | Analysis and regulation of food intake |
| US8423130B2 (en) * | 2008-05-09 | 2013-04-16 | Metacure Limited | Optimization of thresholds for eating detection |
| MX2011000847A (es) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Proteinas conjugadas con eficacia prolongada in vivo. |
| JP5816097B2 (ja) | 2009-01-22 | 2015-11-18 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
| EP2482840A4 (en) * | 2009-08-07 | 2013-06-26 | Mannkind Corp | VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME |
| EP2525834B1 (en) | 2010-01-22 | 2019-07-17 | Novo Nordisk Health Care AG | Growth hormones with prolonged in-vivo efficacy |
| JP5980689B2 (ja) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
| US20130123460A1 (en) | 2010-04-30 | 2013-05-16 | Sanwa Kagaku Kenkyusho Co., Ltd. | Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| WO2014096150A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| EP2981282B1 (en) | 2013-04-05 | 2020-11-04 | Novo Nordisk Health Care AG | Growth hormone compound formulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US5981488A (en) * | 1997-03-31 | 1999-11-09 | Eli Lillly And Company | Glucagon-like peptide-1 analogs |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
-
2003
- 2003-03-27 PL PL03373658A patent/PL373658A1/xx unknown
- 2003-03-27 NZ NZ535684A patent/NZ535684A/xx unknown
- 2003-03-27 CN CNA038080079A patent/CN1735423A/zh active Pending
- 2003-03-27 KR KR10-2004-7016025A patent/KR20040098063A/ko not_active Application Discontinuation
- 2003-03-27 AU AU2003220403A patent/AU2003220403A1/en not_active Abandoned
- 2003-03-27 WO PCT/US2003/008457 patent/WO2003087139A2/en not_active Application Discontinuation
- 2003-03-27 MX MXPA04009929A patent/MXPA04009929A/es not_active Application Discontinuation
- 2003-03-27 EP EP03716707A patent/EP1496924A4/en not_active Withdrawn
- 2003-03-27 US US10/508,762 patent/US20050164925A1/en not_active Abandoned
- 2003-03-27 IL IL16426603A patent/IL164266A0/xx unknown
- 2003-03-27 BR BR0308904-5A patent/BR0308904A/pt not_active IP Right Cessation
- 2003-03-27 EA EA200401345A patent/EA200401345A1/ru unknown
- 2003-03-27 CA CA002480858A patent/CA2480858A1/en not_active Abandoned
- 2003-03-27 JP JP2003584094A patent/JP2005530732A/ja active Pending
-
2004
- 2004-10-07 ZA ZA200408111A patent/ZA200408111B/xx unknown
- 2004-10-07 HR HRP20040939 patent/HRP20040939A2/hr not_active Application Discontinuation
- 2004-10-08 EC EC2004005345A patent/ECSP045345A/es unknown
- 2004-11-05 NO NO20044815A patent/NO20044815L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005530732A5 (ja) | ||
| JP2007001987A5 (ja) | ||
| ES2444622T3 (es) | Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido N-terminal | |
| ES2883345T3 (es) | Compuestos agonistas del GIP y métodos | |
| ES2291017T3 (es) | Efectos inotropicos y diureticos de la exendina y glp-1. | |
| US11866477B2 (en) | GLP-1 analogues | |
| JP2002526454A5 (ja) | ||
| RU2007134156A (ru) | Ацилированные glp-1 соединения | |
| JP2015528795A5 (ja) | ||
| TWI353250B (en) | Glp-1 pharmaceutical compositions | |
| JP2011526886A5 (ja) | ||
| RU2011117645A (ru) | Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день | |
| JP2011524418A5 (ja) | ||
| KR20120128129A (ko) | 심장 병태의 치료 | |
| US20180280480A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| JP2022176986A (ja) | 制御放出および持続的放出のためのｅｌｐ融合タンパク質 | |
| Youn et al. | Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation | |
| RU2752787C1 (ru) | Пептидный аналог ацилированного оксинтомодулина | |
| KR20230146040A (ko) | 글루카곤 유사 펩타이드-1 수용체 길항물질 | |
| JP2009502976A (ja) | 親水性ペプチド鎮痛薬の経口送達のためのペプチドコンジュゲート | |
| US20240058422A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| WO2017200944A1 (en) | Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof | |
| TW202415676A (zh) | 升糖素樣肽-1受體拮抗劑 | |
| TW202415675A (zh) | 腸促胰島素(incretin)類似物及其用途 | |
| OA20012A (en) | Acylated Calcitonin Mimetics. |